Skip to content

Efficacy of Pilocarpine 1% in Presbyopia

Efficacy of Pilocarpine 1% in Pseudophakia Individuals With Presbyopia

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05578001
Enrollment
25
Registered
2022-10-13
Start date
2022-07-01
Completion date
2023-03-30
Last updated
2022-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia, Pseudophakia

Keywords

Pilocarpine, Presbyopia, Pseudophakia

Brief summary

In this before-after interventional study on patients with presbyopia after cataract surgery, uncorrected distance vision and corrected distance visual acuity are measured and recorded by Snellen chart. Corrected near visual acuity from a distance of 40 cm is measured by the standard near vision chart (Rosenbaum near vision card). Twenty minutes after the administration of pilocarpine 1%, the corrected near and far visual acuity is measured again. Also, the relationship between the difference in average near visual acuity after the administration of 1% pilocarpine in pseudophakic people is measured with iris color and pupil size.

Detailed description

After selecting the study cases, the pupil size in both photopic and scotopic conditions and iris color(based on Simionescu's classification) will be recorded. Uncorrected distance visual acuity(UCDVA) will be measured by Snellen chart. Then the appropriate glasses will be placed according to the person's refraction and the corrected distance visual acuity(BCDVA) will be measured. Without changing the fitted glasses, corrected near visual acuity(BCNVA) is measured from a distance of 40 cm by the standard near vision chart (Rosenbaum near vision card). After this stage, one drop of pilocarpine 1% is prescribed in the patient's eye and 20 minutes later, the corrected near and far visual acuity is measured again. Thirty minutes and 8 hours after the administration of pilocarpine drop, the side effects of the drug, including headache, eye pain, eye redness, eye irritation, tearing, and blurred vision at night, are checked.

Interventions

1 drop of Pilocarpine 1%

Sponsors

Isfahan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Informed consent to participate in the study * Previous uncomplicated cartaract surgery and PCIOL insertion * BCDVA eqaul to or more than 8/10 * Less than 1.5 diopter cylindrical refractive error * Spherical refractive error between -0.5\_+1.5 * No history of previous eye disease * Not using drugs that interact with pilocarpine

Exclusion criteria

* Occurrence of any drug-related complications * Unable to follow up the patient after prescribing the drug

Design outcomes

Primary

MeasureTime frameDescription
Best Corrected Near Visual Acuity20 minutesComparison of the BCNVA before and after instillation of Pilocarpine 1%

Secondary

MeasureTime frameDescription
Best Corrected Distance Visual Acuity20 minutesComparison of the BCDVA before and after instillation of Pilocarpine 1%

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026